076 Growth of the Vulvar Vaginal Atrophy (VVA) Therapy Market

Abstract

Up to about 70% of postmenopausal women representing an estimated 32 million women in the United States have VVA symptoms.1-3 Surveys published in 20134 and 20172 found that only 7% of women with VVA symptoms currently use prescription therapy, indicating a significant unmet need. Some newer products that have expanded the treatment armamentarium, have been approved for moderate to severe dyspareunia over the past few years. In addition, the North American Menopause Society, the International Society for the Study of Women’s Sexual Health, and other medical societies focused on women’s health have developed several initiatives to increase awareness of VVA and the genitourinary syndrome of menopause (GSM), which may include genital symptoms of dryness, burning, and irritation; lack of lubrication and/or discomfort or pain during sexual activity; and urinary symptoms. Newer product approvals, which included innovation, as well as awareness initiatives, may have impacted the size of the VVA treatment market. The objective of this study was to analyze growth of the market for VVA treatment using a large prescription database.